French pharmaceutical group Sanofi said on Monday the U.S. Food and Drug Administration's decision on its investigative drug ...
The pan-European STOXX 600 was up 0.4% at 580.35, as of 0808 GMT, remaining within striking distance of an intraday record ...
In response to an FDA request, Sanofi has submitted an expanded access protocol for tolebrutinib in nrSPMS, underscoring the company's commitment to providing eligible patients with access to this ...
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis. PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint ...
Dow Jones Top Company Headlines at 3 AM ET: Sanofi Multiple Sclerosis Drug Hit by Double Setback | China ... A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback